company background image
ARCT

Arcturus Therapeutics Holdings NasdaqGM:ARCT Stock Report

Last Price

US$17.67

Market Cap

US$468.1m

7D

9.8%

1Y

-48.9%

Updated

05 Dec, 2022

Data

Company Financials +
ARCT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ARCT Stock Overview

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.

Arcturus Therapeutics Holdings Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arcturus Therapeutics Holdings
Historical stock prices
Current Share PriceUS$17.67
52 Week HighUS$48.75
52 Week LowUS$11.70
Beta2.51
1 Month Change-24.42%
3 Month Change28.51%
1 Year Change-48.93%
3 Year Change67.97%
5 Year Change106.43%
Change since IPO76.52%

Recent News & Updates

Recent updates

Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 23
Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

Aug 15
Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)

These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

May 11
These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat

Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?

Jan 22
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Weighed On By Its Debt Load?

Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Using Debt In A Risky Way?

Jul 18
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) Using Debt In A Risky Way?

Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) A Risky Investment?

Mar 27
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) A Risky Investment?

How Much Are Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Insiders Spending On Buying Shares?

Mar 01
How Much Are Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Insiders Spending On Buying Shares?

When Will Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Breakeven?

Jan 25
When Will Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Breakeven?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Slashed Next Year's Revenue Estimates By 49%

Dec 30
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Slashed Next Year's Revenue Estimates By 49%

Does This Valuation Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Imply Investors Are Overpaying?

Dec 29
Does This Valuation Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Imply Investors Are Overpaying?

Rainbows and Unicorns: Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Became A Lot More Optimistic

Dec 08
Rainbows and Unicorns: Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Became A Lot More Optimistic

Imagine Holding Arcturus Therapeutics Holdings (NASDAQ:ARCT) Shares While The Price Zoomed 820% Higher

Dec 02
Imagine Holding Arcturus Therapeutics Holdings (NASDAQ:ARCT) Shares While The Price Zoomed 820% Higher

Shareholder Returns

ARCTUS BiotechsUS Market
7D9.8%4.2%1.5%
1Y-48.9%-7.4%-14.9%

Return vs Industry: ARCT underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: ARCT underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is ARCT's price volatile compared to industry and market?
ARCT volatility
ARCT Average Weekly Movement12.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: ARCT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ARCT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013177Joe Paynehttps://arcturusrx.com

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company’s development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis.

Arcturus Therapeutics Holdings Inc. Fundamentals Summary

How do Arcturus Therapeutics Holdings's earnings and revenue compare to its market cap?
ARCT fundamental statistics
Market CapUS$468.13m
Earnings (TTM)-US$146.66m
Revenue (TTM)US$51.50m

9.1x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ARCT income statement (TTM)
RevenueUS$51.50m
Cost of RevenueUS$0
Gross ProfitUS$51.50m
Other ExpensesUS$198.16m
Earnings-US$146.66m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-5.54
Gross Margin100.00%
Net Profit Margin-284.78%
Debt/Equity Ratio41.0%

How did ARCT perform over the long term?

See historical performance and comparison